Elizabeth J. Galbreath, DVM, PhD, DACVP – Senior Pathologist, Manager EPL-Boston, MA
Dr. Elizabeth Galbreath joins Experimental Pathology Laboratories, Inc. (EPL) as a Senior Pathologist and Manager of EPL-Boston, MA. In addition, Dr. Galbreath will be available as a Principal Consultant for Aclairo Pharmaceutical Development Group Inc, an EPL company. Dr. Galbreath will be available to integrate with a client’s preclinical study efforts to provide consultation services in study design, primary histopathology evaluation, pathology peer review, and either participating, organizing, or conducting pathology working groups. Dr. Galbreath has been engaged in biopharmaceutical research and development for more than 25 years.
Dr. Galbreath received her DVM degree from Michigan State University, and her MS and PhD from the University of Wisconsin-Madison emphasizing molecular biology, genetically engineered animal models, and neuropathology. She is certified by the American College of Veterinary Pathologists (ACVP) in anatomical pathology.
Before joining EPL, Dr. Galbreath gained extensive pharmaceutical industry research and development experience in management, scientific, program/project development team, and study pathologist roles at Bristol-Myers Squibb, Eli Lilly and Company, Amgen, Shire, and Takeda. At Eli Lilly she was the Bioproducts and Research Technologies Head of Experimental and Investigative Pathology and served on the Bioproduct Strategy Group corporate governance committee for recombinant proteins and antibodies. Her thorough understanding of gene engineering and assays for assessment, validation, and interpretation of gene expression, along with in-depth experience in biopharmaceutical development, were essential in guiding strategic development in protein, antibody, cell, and gene therapeutic programs throughout her industry career.
Dr. Galbreath is active in, and has been an invited speaker for, many professional organizations, including the ACVP, Society of Toxicologic Pathology (STP), the European Society of Toxicologic Pathology (ESTP), the American Society American Society of Gene & Cell Therapy (ASGCT), and The American Society for Investigative Pathology, serving on numerous committees, such as the STP Scientific and Regulatory Policy Committee, STP Annual Meeting Committee, and chairing/co-chairing many years of the annual ACVP/ASIP session at the annual Experimental Biology meeting of the Federated American Societies of Experimental Biology (FASEB).
In addition to her industry experience and recognized expertise in neuropathology, molecular pathology, biotherapeutics, nucleotide, and gene therapy, Dr. Galbreath has been the author, co-author, or senior author on more than 60 peer-reviewed book chapters and journal publications including in Toxicologic Pathology, Molecular Therapy, and Nature.
Expertise and Interests
- Toxicologic and Investigative Pathology
- Neuropathology
- Pathology Peer Review
- Pathology Working Groups
- Leadership Experience within Corporate Portfolio Governance and Multidisciplinary Matrixed Organizations
- Scientific and Pharmaceutical Development Strategy
- Due Diligence Assessment of Therapeutic Assets and Biopharma Companies
- Biotherapeutic and Gene Therapy Preclinical and Clinical Strategy and Development
- Translational Medicine/Research and Animal Models of Human Disease: Development, Characterization, and Validation, In Vivo and Ex-Vivo Imaging
- Molecular Pathology Assay Development and Validation: In Situ Hybridization and Immunohistochemistry, Spatial Molecular Profiling